Embla Medical hf. (OSSUY)

OTCMKTS · Delayed Price · Currency is USD
4.000
-0.480 (-10.71%)
At close: May 8, 2025
-10.71%
Market Cap1.97B
Revenue (ttm)873.51M
Net Income (ttm)73.14M
Shares Outn/a
EPS (ttm)0.17
PE Ratio26.96
Forward PE21.72
Dividendn/a
Ex-Dividend Daten/a
Volume1,501
Average Volume587
Open4.000
Previous Close4.480
Day's Range4.000 - 4.000
52-Week Range3.760 - 11.000
Beta0.57
RSI46.63
Earnings DateOct 21, 2025

About Embla Medical

Embla Medical hf., together with its subsidiaries, provides non-invasive orthopedic products in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. It operates through three segments: Prosthetics and Neuro Orthotics, Bracing and Supports, and Patient Care. The Prosthetics and Neuro Orthotics segment offers mechanical products, such as lower and upper limb loss or difference; and bionic products microprocessor-controlled feet, knees, hands, fingers, and neuro orthotic joints. Its Bracing and Supports segment provides bracing and... [Read more]

Sector Healthcare
Founded 1971
Employees 4,061
Stock Exchange OTCMKTS
Ticker Symbol OSSUY
Full Company Profile

Financial Performance

In 2024, Embla Medical's revenue was $854.89 million, an increase of 8.81% compared to the previous year's $785.68 million. Earnings were $68.28 million, an increase of 16.94%.

Financial Statements

News

Embla Medical hf: Embla Medical closes the majority share investment in Streifeneder ortho.production GmbH

Announcement no. 39/2025 29 August 2025   Reference is made to announcement no.

15 days ago - PRNewsWire

Embla Medical hf: Embla Medical signs agreement to invest in a majority share in Streifeneder ortho.production GmbH

Announcement no. 31/2025 17 July 2025 REYKJAVIK, Iceland and COPENHAGEN, Denmark , July 17, 2025 /PRNewswire/ -- Embla Medical (NASDAQ Copenhagen: EMBLA), a leading global provider of innovative mobil...

2 months ago - PRNewsWire

Embla Medical hf: Interim Report Q3 2024

Announcement no. 12/2024 Interim report Q3 2024 22 October 2024 COPENHAGEN, Denmark , Oct. 22, 2024 /PRNewswire/ --  Sveinn Sölvason, President and CEO, comments: "We delivered solid sales in the thir...

11 months ago - PRNewsWire

Embla Medical hf: Interim Report Q2 2024

COPENHAGEN, Denmark , July 23, 2024 /PRNewswire/ --          D elivering our highest ever quarterly sales amounting to USD 217 million Organic growth of 6% for Q2 driven strong performance in Prosthet...

1 year ago - PRNewsWire

Ukrainian medical professionals receive comprehensive training in the field of lower limb prosthetics: Össur

REYKJAVIK, Iceland , Oct. 16, 2023 /PRNewswire/ -- Össur (Nasdaq: OSSR), a leading global provider of innovative mobility solutions, recently conducted its first multi-disciplinary educational event f...

2 years ago - PRNewsWire